High-risk prostate cancer: A disease of genomic instability

被引:26
|
作者
Tapia-Laliena, Maria A. [1 ]
Korzeniewski, Nina [1 ]
Hohenfellner, Markus [1 ]
Duensing, Stefan [1 ]
机构
[1] Heidelberg Univ, Sch Med, Dept Urol, Heidelberg, Germany
关键词
Prostate cancer; Genomic instability; Somatic mutations; DNA damage; Translational therapeutics; Biomarkers; IN-SITU HYBRIDIZATION; DNA-REPAIR; CHROMOSOME INSTABILITY; GENETIC INSTABILITY; ERG; FUSION; REARRANGEMENT; MUTATIONS; DELETIONS; CHROMOTHRIPSIS;
D O I
10.1016/j.urolonc.2014.02.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: In this review, we will discuss the latest advances in our understanding of the relationship between the cellular DNA damage response and genomic instability in prostate cancer and the emerging possibilities to exploit these aberrations as prognostic biomarkers and guides for personalized patient management. Methods: Important findings related to genomic instability in prostate cancer were retrieved from the literature and combined with our own results and a translational perspective. Results: Prostate cancer is characterized by a highly altered genomic landscape with a wide spectrum of genomic alterations, including somatic mutations, copy number alterations (CNAs), gene fusions, complex chromosomal rearrangements, and aneuploidy. In addition, massive DNA damaging events, including chromothripsis and chromoplexy, which can lead to extensive genomic insults in a single step, have been identified. A number of these genomic aberrations have been found to provide prognostic information and can therefore help to identify high-risk patients. In addition, defects in the DNA damage checkpoint and repair machinery can potentially be harnessed for therapeutic purposes. Conclusions: Genomic instability plays a crucial role in the malignant progression of prostate cancer and can be exploited for the development of novel prognostic biomarkers and innovative therapies. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:1101 / 1107
页数:7
相关论文
共 50 条
  • [31] High-risk prostate cancer—classification and therapy
    Albert J. Chang
    Karen A. Autio
    Mack Roach
    Howard I. Scher
    Nature Reviews Clinical Oncology, 2014, 11 : 308 - 323
  • [32] Postoperative radiotherapy for high-risk prostate cancer
    Haines, Ian
    LANCET, 2013, 381 (9872): : 1093 - 1093
  • [33] Radical prostatectomy for high-risk prostate cancer
    Yossepowitch, Ofer
    Eastham, James A.
    WORLD JOURNAL OF UROLOGY, 2008, 26 (03) : 219 - 224
  • [34] Concurrent chemoradiation for high-risk prostate cancer
    Cooper, Benjamin T.
    Sanfilippo, Nicholas J.
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2015, 6 (04): : 35 - 42
  • [35] Management of High-Risk Localized Prostate Cancer
    Marciscano, Ariel E.
    Hardee, Matthew E.
    Sanfilippo, Nicholas
    ADVANCES IN UROLOGY, 2012, 2012
  • [36] Adjuvant Therapy in High-Risk Prostate Cancer
    Shevach, Jeffrey
    Chaudhuri, Parul
    Morgans, Alicia K.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 45 - 53
  • [37] The role of surgery for high-risk prostate cancer
    Ucer, Oktay
    Muezzinoglu, Talha
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2014, 13 (01): : 21 - 24
  • [38] Approach to the Patient with High-Risk Prostate Cancer
    Mossanen, Matthew
    Krasnow, Ross E.
    Nguyen, Paul L.
    Trinh, Quoc D.
    Preston, Mark
    Kibel, Adam S.
    UROLOGIC CLINICS OF NORTH AMERICA, 2017, 44 (04) : 635 - +
  • [39] Management of High-Risk Localised Prostate Cancer
    Ozen, Haluk
    Yazici, Sertac
    Inci, Kubilay
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (05) : 439 - 447
  • [40] The management of high-risk prostate cancer in 2008
    Fradet, Yves
    WORLD JOURNAL OF UROLOGY, 2008, 26 (03) : 203 - 203